ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 974,34
0,02%
Dow Jones
44 303,40
-0,99%
DAX
21 802,31
0,18%
Brent Oil
75,17
0,74%
Bitcoin
97 661,32
1,21%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Syndax Pharmaceuticals Inc (SNDX) Cours

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc (SNDX)

NASDAQ
15,52
-0,30
(-1,90%)
Fermé 08 Février 10:00PM
Retardé de 15 minutes
15,52
0,00
( 0,00% )
Avant marché: 10:09AM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
15,52
Prix Achat
6,25
Prix Vente
16,64
Volume échangé
-
0,00 Fourchette du Jour 0,00
12,06 Plage de 52 semaines 25,34
Cap du marché
1,325B
Clôture Veille
15,52
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
2 397 603
Actions en circulation
85 357 675
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-6,33
Bénéfice par action (BPA)
-2,45
Chiffre d'affairess
-
Bénéfice net
-209,36M

À propos de Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.syndax.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Syndax Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker SNDX. Le dernier cours de clôture d'Syndax Pharmaceuticals était de US$15,52. Au cours de la dernière année, les actions de Syndax Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 12,06 à US$ 25,34.

Syndax Pharmaceuticals compte actuellement 85 357 675 actions en circulation. La capitalisation boursière d'Syndax Pharmaceuticals est de US$1,32 milliard. Syndax Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -6.33.

Flux d'options Syndax Pharmaceuticals (SNDX)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

121k

Calls / Puts

100,00%

Ach. / Vent.

100,00%

OTM / ITM

100,00%

Sweeps Ratio

0,00%

SNDX Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

07 Février 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Février 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Février 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Février 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Février 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Février 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Février 2025
Edgar (US Regulatory)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Feb. 4, 2025 WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Syndax Pharmaceuticals...

04 Février 2025
PR Newswire (US)

Syndax Announces Participation in February Investor Conferences

Syndax Announces Participation in February Investor Conferences PR Newswire WALTHAM, Mass., Jan. 30, 2025 WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a...

30 Janvier 2025
PR Newswire (US)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

22 Janvier 2025
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
11.6912.219812002913.8316.5813.61316837015.05164178CS
42.4218.473282442713.116.5812.06233686814.26553214CS
12-0.94-5.7108140947816.4617.512.06239760314.33757168CS
26-4.53-22.593516209520.0522.512.06171410915.97886918CS
52-6.67-30.058584948222.1925.3412.06139320218.23471788CS
1560.110.71382219338115.4129.8611.215110289518.8934782CS
2605.7759.17948717959.7529.866.8889902018.74966915CS

SNDX - Frequently Asked Questions (FAQ)

What is the current Syndax Pharmaceuticals share price?
The current share price of Syndax Pharmaceuticals is US$ 15,52
How many Syndax Pharmaceuticals shares are in issue?
Syndax Pharmaceuticals has 85 357 675 shares in issue
What is the market cap of Syndax Pharmaceuticals?
The market capitalisation of Syndax Pharmaceuticals is USD 1,32B
What is the 1 year trading range for Syndax Pharmaceuticals share price?
Syndax Pharmaceuticals has traded in the range of US$ 12,06 to US$ 25,34 during the past year
What is the PE ratio of Syndax Pharmaceuticals?
The price to earnings ratio of Syndax Pharmaceuticals is -6,33
What is the reporting currency for Syndax Pharmaceuticals?
Syndax Pharmaceuticals reports financial results in USD
What is the latest annual profit for Syndax Pharmaceuticals?
The latest annual profit of Syndax Pharmaceuticals is USD -209,36M
What is the registered address of Syndax Pharmaceuticals?
The registered address for Syndax Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Syndax Pharmaceuticals website address?
The website address for Syndax Pharmaceuticals is www.syndax.com
Which industry sector does Syndax Pharmaceuticals operate in?
Syndax Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PNBKPatriot National Bancorp Inc
US$ 2,50
(72,41%)
5,9M
BSBKBogota Financial Corporation
US$ 12,60
(58,63%)
6
LCNBLCNB Corporation
US$ 24,49
(57,39%)
8
FUSBFirst US Bancshares Inc
US$ 19,99
(56,17%)
1
SPOKSpok Holdings Inc
US$ 24,99
(53,97%)
8
PLRXPliant Therapeutics Inc
US$ 3,43
(-55,97%)
94,65k
FENCFennec Pharmaceuticals Inc
US$ 3,00
(-54,89%)
105
OCSOculis Holding AG
US$ 10,01
(-54,81%)
1
ANIKAnika Therapeutics Inc
US$ 9,01
(-49,35%)
8
FXNCFirst National Corporation
US$ 15,01
(-43,36%)
27
MGOLMGO Global Inc
US$ 0,5602
(34,99%)
23,54M
CYNCYNGN Inc
US$ 0,0776
(28,90%)
19,74M
STBXStarBox Group Holdings Ltd
US$ 0,5045
(51,73%)
8,68M
NIVFNewGenIvf Group Ltd
US$ 0,1599
(19,33%)
8,35M
PNBKPatriot National Bancorp Inc
US$ 2,50
(72,41%)
5,9M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
SNDX
Syndax Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces